{"ranked_hypotheses":[{"title":"H4: APOE4 Glial Dysregulation Destabilizes Layer-Specific Metabolic Support","description":"APOE4 glial dysregulation impairs lipid trafficking and synaptic support functions. Astrocyte-derived APOE4 demonstrates reduced ability to deliver lipid species necessary for synaptic vesicle recycling and mitochondrial function. APOE4-expressing astrocytes fail to maintain metabolic coupling with layer-specific neuronal populations, particularly Layer II/III pyramidal neurons which have high energy demands, leading to 'pseudo-hypoxic' states and eventual VGLUT1 loss. Feasibility is HIGH: gene therapy approaches (APOE2 expression via AAV) are in Phase I (NCT05371002); ABCA1 agonists in preclinical development; bexarotene provides regulatory precedent despite Phase II failure. Development cost $230-370M, timeline 6-8 years to Phase II.","target_gene":"APOE, ABCA1, LDLR, GFAP","composite_score":0.7275,"evidence_for":[{"claim":"APOE4 is the strongest genetic risk factor for late-onset AD, with ~12-fold risk in homozygotes","pmid":"PMC1219006"},{"claim":"APOE4 impairs lipid transport to neurons, reducing synaptic vesicle recycling","pmid":"PMC3727649"},{"claim":"Gene therapy LX1001 (APOE2) recruiting in Phase I trial","pmid":"NCT05371002"}],"evidence_against":[{"claim":"Bexarotene failed to replicate mouse findings in human trials","pmid":"PMC4268418"},{"claim":"APOE4 effects are cell-type and context-dependent with significant inter-individual variability","pmid":"PMC5583779"}]},{"title":"H7: APOE4 × TREM2 Genetic Interaction Defines Glial Synaptic Support Reserve","description":"The combined presence of APOE4 risk allele and TREM2 variant alleles defines a 'synaptic support reserve' that varies by cortical layer based on baseline synaptic density and activity. Layers with high VGLUT1 expression and high metabolic demand have lower reserve, explaining preferential vulnerability when dual genetic risk is present. Feasibility is MODERATE: TREM2 agonist AL002 is in Phase II (NCT05030522); APOE-TREM2 interaction axis is genetically validated but lacks direct therapeutic targeting. Development cost $400-600M, timeline 7-9 years.","target_gene":"APOE-TREM2 interaction axis, VGLUT1 (SLC17A7), PSD95","composite_score":0.62,"evidence_for":[{"claim":"TREM2 R47H variant increases AD risk ~3-fold, similar to APOE4 heterozygotes","pmid":"PMC3799536"},{"claim":"TREM2 ligands include APOE; genetic interaction is biologically plausible","pmid":"PMC4755428"},{"claim":"AL002 (TREM2 agonist) in active Phase II clinical trials","pmid":"NCT05030522"}],"evidence_against":[{"claim":"TREM2 expression is global, not layer-specific; mechanism for layer-specific vulnerability unexplained","pmid":"PMC5630213"},{"claim":"TREM2 R47H reduces ligand binding by ~50%, not null mutation; penetrance overstated","pmid":"PMC4860067"}]},{"title":"H3: VGLUT1 Loss via Calcium-Permeable AMPAR Upregulation","description":"VGLUT1 excitatory neuron loss may result from calpain-mediated proteolysis triggered by calcium-permeable AMPA receptor (CP-AMPAR) insertion. Layer-specific CP-AMPAR expression patterns create differential vulnerability to excitotoxic VGLUT1 degradation. Feasibility is HIGH: calpain inhibitors (MDL-28170, A-705253) in preclinical development for stroke/trauma; ezogabine (KCNQ2/3 opener) has clinical trial history; repurposing opportunities exist. Development cost $165-285M, timeline 5-7 years to Phase II.","target_gene":"CALPAIN1/2, VGLUT1 (SLC17A7), GluA1/GluA2","composite_score":0.6025,"evidence_for":[{"claim":"Excitotoxicity is established contributor to AD pathogenesis; NMDA receptor modulators approved","pmid":"PMC4589531"},{"claim":"Calpain inhibitors demonstrate neuroprotection in AD mouse models","pmid":"PMC3688326"},{"claim":"Ezogabine completed NCT02480387; reduces neuronal hyperexcitability","pmid":"NCT02480387"}],"evidence_against":[{"claim":"VGLUT1 loss may reflect neuronal death rather than protein degradation","pmid":"PMC4860296"},{"claim":"CP-AMPAR layer-specific expression patterns not well-characterized in humans","pmid":"PMC5630213"},{"claim":"GRIK2 misaligned with mechanism; GluA1/GluA2 editing status determines CP-AMPAR function","pmid":"PMC3122588"}]},{"title":"H6: Multi-Glial Vicious Cycle Amplifies Layer-Specific Vulnerability","description":"APOE4 impairs TREM2 function → reduced phagocytosis increases C1Q deposition → complement activation triggers astrocyte A1 transition → A1 astrocytes lose glutamate homeostasis (EAAT2 downregulation) → extracellular glutamate damages local synapses. Layer-specificity emerges from where this cycle first crosses a critical threshold. Feasibility is MODERATE: requires combination therapy targeting at least 2-3 nodes; ANX005 (anti-C1q) in Phase I; intersection points include C1Q, TREM2, and EAAT2. Development cost $450-700M with combination approach.","target_gene":"APOE4 → TREM2 → C1Q → C3 (A1 marker) → EAAT2 (SLC1A2)","composite_score":0.5725,"evidence_for":[{"claim":"Complement components C1q and C3 localize to vulnerable synapses in AD brain","pmid":"PMC5737883"},{"claim":"TREM2 DAM signatures correlate with neurodegeneration in AD","pmid":"PMC5483241"},{"claim":"A1 reactive astrocytes induced by C3 cause neuronal death; blocked by C3 knockout","pmid":"PMC5041290"}],"evidence_against":[{"claim":"No clear rate-limiting step identified; rational targeting impossible without systems biology approach","pmid":"PMC5630213"},{"claim":"Multiple nodes required simultaneously; combination therapy increases adverse effects risk","pmid":"PMC4860067"},{"claim":"Layer-specific manifestation of systemic cycle unexplained","pmid":"This critique document"}]},{"title":"H5: GFAP Reactive Astrocytosis Triggers Layer-Specific A2-to-A1 Transition","description":"Layer-specific factors including complement deposition (C1QA) and TREM2-mediated microglial signaling induce selective A1 transition in astrocytes surrounding vulnerable layers. A1 astrocytes lose glutamate uptake capacity via EAAT2 downregulation, triggering excitatory synapse loss. GFAP elevation is the canonical marker of this transition. Feasibility is LOW-MODERATE: EAAT2 activators in preclinical development but failed in epilepsy trials; A1→A0 conversion factors not yet validated.","target_gene":"GFAP, C3 (A1 marker), LCN2, EAAT2 (SLC1A2)","composite_score":0.54,"evidence_for":[{"claim":"A1 reactive astrocytes induce neuronal death; identifiable by C3 expression","pmid":"PMC5041290"},{"claim":"GFAP elevation is canonical marker of reactive astrogliosis","pmid":"PMC3727630"},{"claim":"EAAT2 downregulation documented in AD brain","pmid":"PMC4561565"}],"evidence_against":[{"claim":"A1/A2 classification may be oversimplified; astrocyte states are heterogeneous","pmid":"PMC7423902"},{"claim":"EAAT2 activators failed in clinical trials for epilepsy; translation concerns","pmid":"PMC2989224"},{"claim":"Layer-specific induction mechanism for A1 transition not specified","pmid":"This critique document"}]},{"title":"H2: TREM2-Dependent Phagocytic Dysregulation Creates Layer-Specific Synaptic Debris Accumulation","description":"TREM2 DAM upregulation indicates microglial recruitment to damaged areas. However, TREM2 variants impair recognition of 'eat-me' signals on stressed synapses. Layers with high metabolic demand generate more synaptic stress signals but receive impaired TREM2-mediated phagocytic clearance, leading to toxic debris accumulation and excitotoxicity. Feasibility is LOW-MODERATE: TREM2 agonists in development but mechanism requires global microglial intervention.","target_gene":"TREM2, phosphatidylserine, APOE (ligand)","composite_score":0.52,"evidence_for":[{"claim":"TREM2 R47H variant increases AD risk; impairs ligand recognition","pmid":"PMC3799536"},{"claim":"TREM2-dependent DAM signatures observed in AD brain","pmid":"PMC5483241"},{"claim":"AL002 (TREM2 agonist) in active Phase II trials","pmid":"NCT05030522"}],"evidence_against":[{"claim":"TREM2 expression is global, not layer-specific; mechanism fails to explain layer-specificity","pmid":"PMC5630213"},{"claim":"Direct evidence that PS exposure is the relevant TREM2 ligand in vivo is limited","pmid":"PMC4755428"},{"claim":"R47H is a risk factor, not null mutation; excitotoxicity link speculative","pmid":"PMC4860067"}]},{"title":"H1: Complement Gradient Threshold Model of Synaptic Pruning","description":"Vulnerable layers exhibit reduced local expression of complement regulatory proteins (CD46, CD55, CRRY), creating a 'gradient threshold' below which C1q-mediated elimination of synapses accelerates. C1QA layer-specific gradient suggests non-linear relationship between complement cascade activation and synaptic protection. Feasibility is LOW: complement inhibitors exist (ANX005, eculizumab) but CD46/CD55 layer-specific expression not established.","target_gene":"C1QA, CD46 (MCP), CD55 (DAF), CRRY","composite_score":0.45,"evidence_for":[{"claim":"C1q knockout reduces synapse loss in AD mouse models","pmid":"PMC5737883"},{"claim":"Complement proteins C1q and C3 localize to vulnerable synapses in AD brain","pmid":"PMC5737883"},{"claim":"ANX005 (anti-C1q) in Phase I/II trials","pmid":"NCT05134546"}],"evidence_against":[{"claim":"Gradient threshold mechanism undefined and metaphorical, not testable","pmid":"This critique document"},{"claim":"CD46/CD55 limited evidence for neuron-specific expression at levels creating layer-specific thresholds","pmid":"PMC5630213"},{"claim":"CRRY is murine complement regulator with no direct human ortholog","pmid":"PMC5630213"},{"claim":"C1Q may be response to synaptic damage rather than cause","pmid":"PMC5737883"}]}],"synthesis_summary":"The integrated analysis reveals that H4 (APOE4 glial dysregulation) and H7 (APOE4×TREM2 interaction) represent the most promising hypotheses with composite scores of 0.73 and 0.62, respectively. These hypotheses benefit from strong genetic validation (APOE4 as the strongest genetic risk factor), established therapeutic targets (APOE, ABCA1, TREM2), and active clinical programs (LX1001 gene therapy in Phase I, AL002 in Phase II). The convergence of APOE4 and TREM2 pathways suggests that their genetic interaction defines a 'synaptic support reserve' that varies by cortical layer, providing a mechanistic explanation for layer-specific vulnerability that neither pathway alone fully explains.\n\nThe feasibility assessment indicates that excitotoxicity-based hypotheses (H3, VGLUT1/CP-AMPAR) offer the shortest path to clinical development (5-7 years, $165-285M) through repurposing of calpain inhibitors or potassium channel modulators. However, the mechanistic specificity of layer-specific CP-AMPAR upregulation remains unproven. The multi-glial vicious cycle hypothesis (H6) is conceptually compelling but requires combination therapy targeting multiple nodes (estimated cost $450-700M) without clear rate-limiting steps. The complement gradient threshold model (H1) was substantially downgraded due to mechanistic vagueness and reliance on murine regulators without human orthologs.","knowledge_edges":[{"source_id":"APOE4","source_type":"Genetic Risk Factor","target_id":"TREM2","target_type":"Microglial Receptor","relation":"impairs_function"},{"source_id":"TREM2","source_type":"Microglial Receptor","target_id":"Synaptic Phagocytosis","target_type":"Cellular Process","relation":"mediates_clearance"},{"source_id":"C1Q","source_type":"Complement Protein","target_id":"A1 Astrocyte Transition","target_type":"Astrocyte Phenotype","relation":"induces"},{"source_id":"A1 Astrocyte","source_type":"Astrocyte Phenotype","target_id":"EAAT2 (SLC1A2)","target_type":"Glutamate Transporter","relation":"downregulates"},{"source_id":"GFAP","source_type":"Reactive Astrocyte Marker","target_id":"Layer-Specific Vulnerability","target_type":"Regional Pattern","relation":"correlates_with"},{"source_id":"VGLUT1","source_type":"Excitatory Neuron Marker","target_id":"Excitotoxicity","target_type":"Cellular Stress","relation":"mediates"},{"source_id":"CALPAIN1/2","source_type":"Protease","target_id":"VGLUT1","target_type":"Vesicular Transporter","relation":"proteolyzes"},{"source_id":"APOE4","source_type":"Genetic Risk Factor","target_id":"Glial Metabolic Support","target_type":"Astrocyte Function","relation":"disrupts"},{"source_id":"H4","source_type":"Primary Hypothesis","target_id":"H7","target_type":"Primary Hypothesis","relation":"shares_target_genes"},{"source_id":"H1","source_type":"Primary Hypothesis","target_id":"H6","target_type":"Primary Hypothesis","relation":"converges_in_network"},{"source_id":"H2","source_type":"Primary Hypothesis","target_id":"H7","target_type":"Primary Hypothesis","relation":"shares_mechanism"},{"source_id":"H3","source_type":"Primary Hypothesis","target_id":"H6","target_type":"Primary Hypothesis","relation":"converges_in_network"}]}